Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

NCT00327327 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG: imexon
DRUG: gemcitabine

Sponsor

AmpliMed Corporation